1
|
Russo J, Yang X, Hu YF, Bove BA, Huang Y,
Silva ID, Tahin Q, Wu Y, Higgy N, Zekri A and Russo IH: Biological
and molecular basis of human breast cancer. Front Biosci.
3:D944–D960. 1998. View
Article : Google Scholar : PubMed/NCBI
|
2
|
Werner M, Mattis A, Aubele M, Cummings M,
Zitzelsberger H, Hutzler P and Höfler H: 20q13.2 amplification in
intraductal hyperplasia adjacent to in situ and invasive ductal
carcinoma of the breast. Virchows Arch. 435:469–472. 1999.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Harris JR and Hellman S: Natural history
of breast cancerDiseases of the Breast. Harris JR, Lippman ME,
Morrow M and Hellman S: Lippincott Raven; Philadelphia, PA: pp.
375–391. 1996
|
4
|
Lakhani SR: The transition from
hyperplasia to invasive carcinoma of the breast. J Pathol.
187:272–278. 1999. View Article : Google Scholar : PubMed/NCBI
|
5
|
Werner M, Mattis A, Aubele M, Cummings M,
Zitzelsberger HH, Hhutzler P and Höfler H: 20q13.2 amplification in
intraductal hyperplasia adjacent to in situ and invasive ductal
carcinoma of the breast. Virchows Arch. 435:469–472. 1999.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Eiriksdottir G, Sigurdsson A, Jonasson JG,
Agnarsson BA, Sigurdsson H, Gudmundsson J, Bergthorsson JT,
Barkardottir RB, Egilsson V and Ingvarsson S: Loss of
heterozygosity on chromosome 9 in human breast cancer: Association
with clinical variables and genetic changes at other chromosome
regions. Int J Cancer. 64:378–382. 1995. View Article : Google Scholar : PubMed/NCBI
|
7
|
Kuukasjärvi T, Karhu R, Tanner M, Kähkönen
M, Schäffer A, Nupponen N, Pennanen S, Kallioniemi A, Kallioniemi
OP and Isola J: Genetic heterogeneity and clonal evolution
underlying development of asynchronous metastasis in human breast
cancer. Cancer Res. 57:1597–1604. 1997.PubMed/NCBI
|
8
|
Fujii H, Marsh C, Cairns P, Sidransky D
and Gabrielson E: Genetic divergence in the clonal evolution of
breast cancer. Cancer Res. 56:1493–1497. 1996.PubMed/NCBI
|
9
|
Czerniak B, Chatuverdi V, Li L, Hodges S,
Johnston D, Ro JY, Luthra R, Logothetis C, Von Eschenbach AC,
Grossman HB, et al: Superimposed histologic and genetic mapping of
chromosome 9 in progression of human urinary bladder neoplasia:
Implications for a genetic model of multistep carcinogenesis and
early detection of urinary bladder cancer. Oncogene. 18:1185–1196.
1999. View Article : Google Scholar : PubMed/NCBI
|
10
|
Campbell IG, Foulkes WD, Beynon G, Davis M
and Englefield P: LOH and mutation analysis of CDKN2 in primary
human ovarian cancers. Int J Cancer. 63:222–225. 1995. View Article : Google Scholar : PubMed/NCBI
|
11
|
Nakanishi H, Wang XL, Imai FL, Kato J,
Shiiba M, Myia T, Imai Y and Tanzawa H: Localization of a novel
tumor suppressor gene loci on chromosome 9p21-22 in oral cancer.
Anticancer Res. 19:29–34. 1999.PubMed/NCBI
|
12
|
Murphy DS, Hoare SF, Going JJ, Mallon EE,
George WD, Kaye SB, Brown R, Black DM and Keith WN:
Characterization of extensive genetic alterations in ductal
carcinoma in situ by fluorescence in situ hybridization and
molecular analysis. J Natl Cancer Inst. 87:1694–1704. 1995.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Berns EM, Klijn JG, Smid M, Van Staveren
IL, Gruis NA and Foekens JA: Infrequent CDKN2 (MTS1/p16) gene
alterations in human primary breast cancer. Br J Cancer.
72:964–967. 1995. View Article : Google Scholar : PubMed/NCBI
|
14
|
Quesnel B, Fenaux P, Philippe N, Fournier
J, Bonneterre J, Preudhomme C and Peyrat JP: Analysis of p16 gene
deletion and point mutation in breast carcinoma. Br J Cancer.
72:351–353. 1995. View Article : Google Scholar : PubMed/NCBI
|
15
|
Xu L, Sgroi D, Sterner CJ, Beauchamp RL,
Pinney DM, Keel S, Ueki K, Rutter JL, Buckler AJ and Louis DN:
Mutational analysis of CDKN2 (MTS1/p16INK4) in human breast
carcinomas. Cancer Res. 54:5262–5264. 1994.PubMed/NCBI
|
16
|
Brenner AJ and Aldaz M: Chromosome 9p
allelic loss and p16/CDK_N2 in breast cancer and evidence of p16
inactivation in immortal breast epithelial cells. Cancer Res.
55:2892–2895. 1995.PubMed/NCBI
|
17
|
An HX, Niederacher D, Picard F, Van Roeyen
C, Bender HG and Beckmann MW: Frequent allele loss on 9p21-22
defines a smallest common region in the vicinity of the CDKN2 gene
in sporadic breast cancer. Genes Chromosomes Cancer. 17:14–20.
1996. View Article : Google Scholar : PubMed/NCBI
|
18
|
Minobe K, Onda M, Iida A, Kasumi F,
Sakamoto G, Nakamura Y and Emi M: Allelic loss on chromosome 9q is
associated with lymph node metastasis of primary breast cancer. Jpn
J Cancer Res. 89:916–922. 1998. View Article : Google Scholar : PubMed/NCBI
|
19
|
Cairns P, Polascik TJ, Eby Y, Tokino K,
Califano J, Merlo A, Mao L, Heath J, Jenkins R, Westra W, et al:
Frequency of homozygous deletion at p16/CDKN2 in primary human
tumors. Nat Genet. 11:210–212. 1995. View Article : Google Scholar : PubMed/NCBI
|
20
|
Dutrilaux B, Gerbault-Senreau M and
Zafrani B: Characterization of chromosomal abnormalities in human
breast cancer. A comparison of 30 paradiploid cases with few
chromosome changes. Cancer Genet Cytogenet. 49:203–217.
1990.PubMed/NCBI
|
21
|
Emmert-Buck MR, Bonner RF, Smith PD,
Chuaqui RF, Zhuang Z, Goldstein SR, Weiss RA and Liotta LA: Laser
capture microdissection. Science. 274:998–1001. 1996. View Article : Google Scholar : PubMed/NCBI
|
22
|
Bonner RF, Emmert-Buck M, Cole K, Pohida
T, Chuaqui R, Goldstein S and Liotta LA: Laser capture
microdissection: Molecular analysis of tissue. Science.
278:1481–1483. 1997. View Article : Google Scholar : PubMed/NCBI
|
23
|
Simone NL, Bonner RF, Gillespie JW,
Emmert-Buck MR and Liotta LA: Laser capture microdissection:
Opening the microscopic frontier to molecular analysis. Trends
Genet. 14:272–276. 1998. View Article : Google Scholar : PubMed/NCBI
|
24
|
Russo J and Russo IH: The pathology of
breast cancer: Staging and prognostic indicators. J Am Med Womens
Assoc (1972). 47:181–187. 1992.PubMed/NCBI
|
25
|
Russo J, Gusterson BA, Rogers AE, Russo
IH, Wellings SR and van Zwieten MJ: Comparative study of human and
rat mammary tumorigenesis. Lab Invest. 62:244–278. 1990.PubMed/NCBI
|
26
|
Kellogg DE, Rybalkin I, Chen S,
Mukhamedova N, Vlasik T, Siebert PD and Chenchik A: TaqStart
Antibody: ‘hot start’ PCR facilitated by a neutralizing monoclonal
antibody directed against Taq DNA polymerase. Biotechniques.
16:1134–1137. 1994.PubMed/NCBI
|
27
|
Wu Y, Barnabas N, Russo IH, Yang X and
Russo J: Microsatellite instability and loss of heterozygosity in
chromosomes 9 and 16 in human breast epithelial cells transformed
by chemical carcinogens. Carcinogenesis. 18:1069–1074. 1997.
View Article : Google Scholar : PubMed/NCBI
|
28
|
Muzeau F, Flejou JF, Thomas G and Hamelin
R: Loss of heterozygosity on chromosome 9 and p16 (MTS1, CDKN2)
gene mutations in esophageal cancers. Int J Cancer. 72:27–30. 1997.
View Article : Google Scholar : PubMed/NCBI
|
29
|
Morita R, Fujimoto A, Hatta N, Takehara K
and Takata M: Comparison of genetic profiles between primary
melanomas and their metastases reveals genetic alterations and
clonal evolution during progression. J Invest Dermatol.
111:919–924. 1998. View Article : Google Scholar : PubMed/NCBI
|
30
|
Deng G, Lu Y, Zlotikov G, Thor AD and
Smith HS: Loss of heterozygosity in normal tissue adjacent to
breast carcinomas. Science. 274:2057–2059. 1996. View Article : Google Scholar : PubMed/NCBI
|
31
|
Nowell PC: The clonal evolution of tumor
cell populations. Science. 194:23–28. 1976. View Article : Google Scholar : PubMed/NCBI
|
32
|
Fialkow PJ: Clonal origin of human tumors.
Biochem Biophys Acta. 458:283–321. 1976.PubMed/NCBI
|
33
|
Noguchi S, Motomura K, Inaji H, Imaoka S
and Koyamma H: Clonal analysis of human breast cancer by means of
the polymerase chain reaction. Cancer Res. 52:6594–6597.
1992.PubMed/NCBI
|
34
|
Teixeira MR, Pandis N, Bardi G, Andersen
JA, Mitelman F and Heim S: Clonal heterogeneity in breast cancer:
karyotypic comparisons of multiple intra- and extra-tumorous
samples from 3 patients. Int J Cancer. 63:63–68. 1995. View Article : Google Scholar : PubMed/NCBI
|
35
|
Teixeira MR, Pandis N, Bardi G, Andersen
JA and Heim S: Karyotypic comparisons of multiple tumors and
macroscopically normal surrounding tissue samples from patients
with breast cancer. Cancer Res. 56:855–859. 1996.PubMed/NCBI
|
36
|
Pandis N, Jin Y, Gorunova L, Petersson C,
Bardi G, Idvall I, Johansson B, Ingvar C, Mandahl N and Mitelman F:
Chromosome analysis of 97 primary breast carcinomas: Identification
of eight karyotypic subgroups. Genes Chromosomes Cancer.
12:173–185. 1995. View Article : Google Scholar : PubMed/NCBI
|
37
|
Böni R, Matt D, Voetmeyer A, Burg G and
Zhuang Z: Chromosomal allele loss in primary melanoma is
heterogeneous and correlates with proliferation. J Invest Dermat.
110:215–217. 1998. View Article : Google Scholar
|
38
|
Ornstein DK, Englert C, Gillespie JW,
Paweletz CP, Linehan WM and Emmert-Buck MR and Petricoin EF III:
Characterization of intracellular prostate-specific antigen from
laser capture microdissected benign and malignant prostatic
epithelium. Clin Cancer Res. 6:353–356. 2000.PubMed/NCBI
|
39
|
Milchgrub S, Wistuba II, Kim BK,
Rutherford C, Urban J, Cruz PD Jr..Gazdar AF: Molecular
identification of metastatic cancer to the skin using laser capture
microdissection: A case report. Cancer. 88:749–754. 2000.
View Article : Google Scholar : PubMed/NCBI
|
40
|
Aubele M, Mattis A, Zitzelsberger H, Walch
A, Kremer M, Hutzler P, Höfler H and Werner M: Intratumoral
heterogeneity in breast carcinoma revealed by laser-microdissection
and comparative genomic hybridization. Cancer Genet Cytogenet.
110:94–102. 1999. View Article : Google Scholar : PubMed/NCBI
|
41
|
Zhuang Z, Merino MJ, Chuaqui R, Liotta LA
and Emmert-Buck MR: Identical allelic loss on chromosome 11q13 in
microdissected in situ and invasive human breast cancer. Cancer
Res. 55:467–471. 1995.PubMed/NCBI
|
42
|
Radford DM, Phillips NJ, Fair KL, Ritter
JH, Holt M and Donis-Keller H: Allelic loss and the progression of
breast cancer. Cancer Res. 55:5180–5183. 1995.PubMed/NCBI
|